View Item 

Show simple item record

V559A and N822I double KIT mutant melanoma with predictable response to imatinib?

dc.contributor.authorMcDonnell, Kevinen_US
dc.contributor.authorBetz, Bryanen_US
dc.contributor.authorFullen, Douglas R.en_US
dc.contributor.authorLao, Christopher D.en_US
dc.date.accessioned2011-12-05T18:35:45Z
dc.date.available2012-05-14T20:40:08Zen_US
dc.date.issued2011-04en_US
dc.identifier.citationMcDonnell, Kevin; Betz, Bryan; Fullen, Douglas; Lao, Christopher D. (2011). "V559A and N822I double KIT mutant melanoma with predictable response to imatinib?." Pigment Cell & Melanoma Research 24(2). <http://hdl.handle.net/2027.42/88125>en_US
dc.identifier.issn1755-1471en_US
dc.identifier.issn1755-148Xen_US
dc.identifier.urihttps://hdl.handle.net/2027.42/88125
dc.publisherBlackwell Publishing Ltden_US
dc.publisherWiley Periodicals, Inc.en_US
dc.titleV559A and N822I double KIT mutant melanoma with predictable response to imatinib?en_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelDermatologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDepartment of Internal Medicine, University of Michigan Medical Center, Ann Arbor, MI, USAen_US
dc.contributor.affiliationumDepartment of Pathology, University of Michigan Medical Center, Ann Arbor, MI, USAen_US
dc.contributor.affiliationumDepartment of Dermatology, University of Michigan Medical Center, Ann Arbor, MI, USAen_US
dc.identifier.pmid21159146en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/88125/1/j.1755-148X.2010.00822.x.pdf
dc.identifier.doi10.1111/j.1755-148X.2010.00822.xen_US
dc.identifier.sourcePigment Cell & Melanoma Researchen_US
dc.identifier.citedreferenceAntonescu, C.R., Besmer, P., Guo, T. et al. ( 2005 ). Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin. Cancer Res., 11, 4182 – 4190.en_US
dc.identifier.citedreferenceCarvajal, R., Chapman, P.B., Wolchok, J.D., Cane, L., Teitcher, J.B., Lutzky, J., Pavlick, A.C., Bastian, B.C., Antonescu, C.R., and Schwartz, G.K. ( 2009 ). A phase II study of imatinib mesylate (IM) for patients with advanced melanoma harboring somatic alterations of KIT. J. Clin. Oncol., 25, 9001.en_US
dc.identifier.citedreferenceCarvajal, R., Chapman, P., Wolchok, J., Cane, L., Teitcer, J., Lutzky, J., Pavlick, A., Bastian, B., Antonescu, R., and Schwartz, G. ( 2009 ). A phase II study of imatinin mesylate (IM) for patients with advanced melanoma harboring somatic alterations of KIT. J. Clin. Oncol., 27, 15s.en_US
dc.identifier.citedreferenceChan, C., Chen, L., Hsueh, Y., Chuang, W., Lee, H., Huang, M., Heieh, R., and Weng, W. ( 2009 ). Differential response of primary or secondary exon 13/14 and exon 17 c‐kit mutant to nilotinib and sunitinib: findings from a cell‐based drug‐screening platform. J. Clin. Oncol., 27, Suppl; abstract e15636.en_US
dc.identifier.citedreferenceChen, L.L., Trent, J.C., Wu, E.F. et al. ( 2004 ). A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res., 64, 5913 – 5919.en_US
dc.identifier.citedreferenceCorless, C.L., and Heinrich, M.C. ( 2008 ). Molecular pathobiology of gastrointestinal stromal sarcomas. Annu. Rev. Pathol., 3, 557 – 586.en_US
dc.identifier.citedreferenceCurtin, J.A., Fridlyand, J., Kageshita, T. et al. ( 2005 ). Distinct sets of genetic alterations in melanoma. N. Engl. J. Med., 353, 2135 – 2147.en_US
dc.identifier.citedreferenceCurtin, J.A., Busam, K., Pinkel, D., and Bastian, B.C. ( 2006 ). Somatic activation of KIT in distinct subtypes of melanoma. J. Clin. Oncol., 24, 4340 – 4346.en_US
dc.identifier.citedreferenceDebiec‐Rychter, M., Cools, J., Dumez, H. et al. ( 2005 ). Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib‐resistant mutants. Gastroenterology, 128, 270 – 279.en_US
dc.identifier.citedreferenceDebiec‐Rychter, M., Sciot, R., Le Cesne, A. et al. ( 2006 ). KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur. J. Cancer, 42, 1093 – 1103.en_US
dc.identifier.citedreferenceGramza, A.W., Corless, C.L., and Heinrich, M.C. ( 2009 ). Resistance to tyrosine kinase inhibitors in gastrointestinal stromal tumors. Clin. Cancer Res., 15, 7510 – 7518.en_US
dc.identifier.citedreferenceGrimpen, F., Yip, D., Mcarthur, G., Waring, P., Goldstein, D., Loughrey, M., Beshay, V., and Chong, G. ( 2005 ). Resistance to imatinib, low‐grade FDG‐avidity on PET, and acquired KIT exon 17 mutation in gastrointestinal stromal tumour. Lancet Oncol., 6, 724 – 727.en_US
dc.identifier.citedreferenceGrowney, J.D., Clark, J.J., Adelsperger, J., Stone, R., Fabbro, D., Griffin, J.D., and Gilliland, D.G. ( 2005 ). Activation mutations of human c‐KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412. Blood, 106, 721 – 724.en_US
dc.identifier.citedreferenceHeinrich, M.C., Corless, C.L., Demetri, G.D. et al. ( 2003 ). Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J. Clin. Oncol., 21, 4342 – 4349.en_US
dc.identifier.citedreferenceHeinrich, M.C., Corless, C.L., Blanke, C.D. et al. ( 2006 ). Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J. Clin. Oncol., 24, 4764 – 4774.en_US
dc.identifier.citedreferenceHodi, F.S., Friedlander, P., Corless, C.L. et al. ( 2008 ). Major response to imatinib mesylate in KIT‐mutated melanoma. J. Clin. Oncol., 26, 2046 – 2051.en_US
dc.identifier.citedreferenceKemmer, K., Corless, C.L., Fletcher, J.A., Mcgreevey, L., Haley, A., Griffith, D., Cummings, O.W., Wait, C., Town, A., and Heinrich, M.C. ( 2004 ). KIT mutations are common in testicular seminomas. Am. J. Pathol., 164, 305 – 313.en_US
dc.identifier.citedreferenceLutzky, J., Bauer, J., and Bastian, B.C. ( 2008 ). Dose‐dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation. Pigment Cell Melanoma Res., 21, 492 – 493.en_US
dc.identifier.citedreferenceRedaelli, S., Piazza, R., Rostagno, R., Magistroni, V., Perini, P., Marega, M., Gambacorti‐Passerini, C., and Boschelli, F. ( 2009 ). Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib‐resistant BCR/ABL mutants. J. Clin. Oncol., 27, 469 – 471.en_US
dc.identifier.citedreferenceSatzger, I., Kuttler, U., Volker, B., Schenck, F., Kapp, A., and Gutzmer, R. ( 2010 ). Anal mucosal melanoma with KIT‐activating mutation and response to imatinib therapy – case report and review of the literature. Dermatology, 220, 77 – 81.en_US
dc.identifier.citedreferenceTamborini, E., Bonadiman, L., Greco, A. et al. ( 2004 ). A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. Gastroenterology, 127, 294 – 299.en_US
dc.identifier.citedreferenceTorres‐Cabala, C.A., Wang, W.L., Trent, J. et al. ( 2009 ). Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral‐lentiginous/mucosal type. Mod. Pathol., 22, 1446 – 1456.en_US
dc.identifier.citedreferenceWardelmann, E., Thomas, N., Merkelbach‐Bruse, S., Pauls, K., Speidel, N., Buttner, R., Bihl, H., Leutner, C.C., Heinicke, T., and Hohenberger, P. ( 2005 ). Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations. Lancet Oncol., 6, 249 – 251.en_US
dc.identifier.citedreferenceWardelmann, E., Merkelbach‐Bruse, S., Pauls, K. et al. ( 2006 ). Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate. Clin. Cancer Res., 12, 1743 – 1749.en_US
dc.identifier.citedreferenceWent, P.T., Dirnhofer, S., Bundi, M. et al. ( 2004 ). Prevalence of KIT expression in human tumors. J. Clin. Oncol., 22, 4514 – 4522.en_US
dc.identifier.citedreferenceWoodman, S.E., and Davies, M.A. ( 2010 ). Targeting KIT in melanoma: a paradigm of molecular medicine and targeted therapeutics. Biochem. Pharmacol., 80, 568 – 574.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1755-148X.2010.00822.x.pdf
Size:
42.89KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.